Want to see SE:IBT.B full AI Analyst Report?
Top Page
Infant Bacterial Therapeutics AB
(IBT.B)
Select Model
Select Model
Rating:48Neutral
Price Target:
kr64.00
▲(1.59% Upside)
Action:Reiterated
Date:09/06/26
The score is primarily held back by weak financial performance (zero revenue, ongoing losses, and persistent cash burn), despite the benefit of a debt-free balance sheet. Technicals are broadly neutral with limited momentum, and valuation is hard to support given negative earnings and no dividend yield data.
Positive Factors
Debt-free balance sheet
Zero debt removes contractual interest obligations and reduces refinancing pressure, giving management more flexibility while clinical development continues. This does not solve funding needs, but it is a durable balance-sheet advantage versus a similarly pre-revenue biotech carrying debt.
Negative Factors
Pre-revenue operating model
The absence of revenue means IBT currently has no demonstrated commercial engine to absorb research and development costs. Substantial operating losses therefore remain dependent on future clinical success, regulatory approval and eventual commercialization or partnering.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero debt removes contractual interest obligations and reduces refinancing pressure, giving management more flexibility while clinical development continues. This does not solve funding needs, but it is a durable balance-sheet advantage versus a similarly pre-revenue biotech carrying debt.
Read all positive factors
Infant Bacterial Therapeutics AB (IBT.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr875.64M
Dividend YieldN/A
Average Volume (3M)9.05K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue GrowthN/A
EPS Growth19.94%
CountrySE
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.09
Shares Outstanding13,018,137
10 Day Avg. Volume18,819
30 Day Avg. Volume9,051
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)6.46
Price to Sales (P/S)0.00
P/FCF Ratio-9.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.72
Revenue Forecast (FY)N/A
Infant Bacterial Therapeutics AB Business Overview & Revenue Model
Company Description
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which...
How the Company Makes Money
Infant Bacterial Therapeutics AB is a clinical-stage biotechnology company and, based on publicly available information, it has not been characterized as generating material recurring revenue from product sales. Its primary economic model is to in...
Infant Bacterial Therapeutics AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 4.00K | 77.00K | 12.00K | 0.00 |
| Gross Profit | 0.00 | 0.00 | 4.00K | 77.00K | 12.00K | 0.00 |
| EBITDA | -82.02M | -68.18M | -136.91M | 11.55M | -64.34M | -43.76M |
| Net Income | -81.92M | -65.17M | -136.91M | -123.07M | -65.45M | -44.99M |
Balance Sheet | ||||||
| Total Assets | 120.22M | 161.75M | 239.57M | 351.33M | 349.62M | 408.48M |
| Cash, Cash Equivalents and Short-Term Investments | 108.60M | 144.01M | 223.39M | 329.06M | 335.84M | 386.75M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 67.20M | 56.42M | 69.30M | 46.18M | 17.91M | 13.22M |
| Stockholders Equity | 53.02M | 105.33M | 170.26M | 305.15M | 331.71M | 395.25M |
Cash Flow | ||||||
| Free Cash Flow | -64.06M | -72.34M | -113.13M | -101.22M | -85.80M | -55.62M |
| Operating Cash Flow | -64.06M | -72.34M | -113.13M | -101.22M | -85.80M | -55.62M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -4.15M | -1.00K | 0.00 |
| Financing Cash Flow | 0.00 | 0.00 | 2.01M | 96.52M | 1.88M | 91.00K |
Infant Bacterial Therapeutics AB Technical Analysis
Positive
63.00
Price Trends
66.00
Negative
61.57
Positive
55.58
Positive
Market Momentum
-0.33
Positive
49.29
Neutral
27.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IBT.B, the sentiment is Positive. The current price of 63 is below the 20-day moving average (MA) of 65.31, below the 50-day MA of 66.00, and above the 200-day MA of 55.58, indicating a neutral trend. The MACD of -0.33 indicates Positive momentum. The RSI at 49.29 is Neutral, neither overbought nor oversold. The STOCH value of 27.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IBT.B.
Infant Bacterial Therapeutics AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr4.71B | -5.89 | ― | ― | -3.57% | 8.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr201.11M | -4.07 | -13.41% | ― | -68.66% | -137.27% | |
48 Neutral | kr875.64M | -10.67 | -89.70% | ― | ― | 19.94% | |
46 Neutral | kr378.30M | -4.19 | -34.25% | ― | -0.71% | 54.16% | |
43 Neutral | kr1.60B | -3.22 | -99.58% | ― | -87.22% | -70.29% | |
41 Neutral | kr31.94M | -0.20 | -104.71% | ― | -2.29% | 55.71% |
* Healthcare Sector Average
SE:IBT.B
Infant Bacterial Therapeutics AB
65.00
-16.50
-20.25%
SE:HNSA
Hansa Biopharma AB
46.26
15.48
50.29%
SE:BINV
BioInvent International AB
24.30
-5.10
-17.35%
SE:XBRANE
Xbrane Biopharma AB
9.76
-23.84
-70.95%
SE:IVACC
Intervacc AB
1.11
-0.05
-4.48%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
1.35
-6.55
-82.96%
Infant Bacterial Therapeutics AB Corporate Events
Infant Bacterial Therapeutics Advances IBP-9414 Toward Market Despite Wider Losses
Aug 26, 2026
Infant Bacterial Therapeutics AB reported no net sales for the first half of 2026 and a widened operating loss, reflecting its pre-commercial stage as it advances its lead neonatal drug candidate IBP-9414 toward market approval. Despite the financ...
Infant Bacterial Therapeutics Announces CFO Departure Amid Late-Stage Drug Push
Jul 7, 2026
Infant Bacterial Therapeutics AB announced that Chief Financial Officer Maria Ekdahl will leave the company on October 7, prompting the appointment of an external consultant to oversee the finance function during the search for a permanent success...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.